Ontology highlight
ABSTRACT:
SUBMITTER: Garnett MJ
PROVIDER: S-EPMC3349233 | biostudies-literature | 2012 Mar
REPOSITORIES: biostudies-literature
Garnett Mathew J MJ Edelman Elena J EJ Heidorn Sonja J SJ Greenman Chris D CD Dastur Anahita A Lau King Wai KW Greninger Patricia P Thompson I Richard IR Luo Xi X Soares Jorge J Liu Qingsong Q Iorio Francesco F Surdez Didier D Chen Li L Milano Randy J RJ Bignell Graham R GR Tam Ah T AT Davies Helen H Stevenson Jesse A JA Barthorpe Syd S Lutz Stephen R SR Kogera Fiona F Lawrence Karl K McLaren-Douglas Anne A Mitropoulos Xeni X Mironenko Tatiana T Thi Helen H Richardson Laura L Zhou Wenjun W Jewitt Frances F Zhang Tinghu T O'Brien Patrick P Boisvert Jessica L JL Price Stacey S Hur Wooyoung W Yang Wanjuan W Deng Xianming X Butler Adam A Choi Hwan Geun HG Chang Jae Won JW Baselga Jose J Stamenkovic Ivan I Engelman Jeffrey A JA Sharma Sreenath V SV Delattre Olivier O Saez-Rodriguez Julio J Gray Nathanael S NS Settleman Jeffrey J Futreal P Andrew PA Haber Daniel A DA Stratton Michael R MR Ramaswamy Sridhar S McDermott Ultan U Benes Cyril H CH
Nature 20120328 7391
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred cancer cell lines--which represent much of the tissue-type and genetic diversity of human cancers--with 130 drugs under clinical and preclinical investigation. In aggregate, we found that mutate ...[more]